Envarsus 0.75 mg prolonged-release tablets
Sponsors
Universitaetsklinikum Regensburg, Centre Hospitalier Universitaire De Limoges, Vall D'hebron Institut De Recerca, Vall D'hebron Institut De Recerca, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Universitaetsklinikum Schleswig-Holstein AöR
Conditions
Caucasian paediatric kidney transplant recipientsICD 10: Z94.4 Liver transplant statusKidney transplantProphylaxis of transplant rejection in adult kidney allograft recipientsProphylaxis of transplant rejection in adult liver allograft recipientsRenal transplantationkidney failure werefor need for kidney transplantkidney transplant
Phase 2
Phase 3
Phase 4
Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients
Active, not recruitingCTIS2023-503531-18-00
Start: 2024-02-13Target: 300Updated: 2025-08-08
A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppression versus stopping immunosuppression at 6 months to safely prevent human leukocyte antigen (HLA) sensitization in patients with late renal graft failure
RecruitingCTIS2023-506879-98-00
Start: 2024-01-22Target: 202Updated: 2024-09-25
Evaluation of the benefits of Administering immunosuppressive drugs as Single daily doses over the first Year after liver transplantation
RecruitingCTIS2023-506601-19-00
Start: 2025-04-15Target: 200Updated: 2025-10-07
Personalized tacrolimus treatment for pediatric kidney transplant recipients by using a dosing algorithm and a once-daily tacrolimus formulation
Not yet recruitingCTIS2024-511585-36-00
Target: 28Updated: 2024-06-28
Cognitive function after liver transplantation comparing Tacrolimus formulations
Active, not recruitingCTIS2024-513963-22-00
Start: 2020-12-09Target: 150Updated: 2025-05-19
Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients
Active, not recruitingCTIS2024-518033-28-00
Start: 2020-11-27Target: 268Updated: 2025-12-03
The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard
IMmunosuppression with tacrolimus and mycophenolate mofetil
with a low exposure tacrolimus regimen In combination with
everolimus in de novo renal transplantation in Elderly patients.
CompletedCTIS2024-516509-22-00
Start: 2019-07-22End: 2025-04-14Target: 381Updated: 2024-11-12
TRANSPGx: A multicentre, controlled, randomised and single-blind, adaptive phase IV protocol to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretransplant chronic kidney disease population cohort
RecruitingCTIS2024-516596-32-00
Start: 2025-03-31Target: 114Updated: 2025-08-08
Personalized Use of Resources Study (PURE)
CompletedCTIS2024-515542-16-03
End: 2025-01-28Target: 25Updated: 2025-01-17